Biophan Technologies, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biophan Technologies, Inc.
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
Start-Up interviews the inventors behind Ardian, the object of one of the highest priced venture capital-backed medical device acquisitions, and between them, five other medical device companies. The team uniquely brings a perspective of applied physiology, and the integration of systems, to the goal of device innovation. In CHF Solutions, they've addressed heart failure with a device from nephrology, in Cardiac Conetps, heart failure by way of a neurological approach to sleep apnea, and in Ardian, hypertension, by studying the functioning of the kidney.
In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking-for July-September 2007. Our data are derived from Windhover's Strategic Transactions Database.
Among imaging modalities used to guide surgery, magnetic resonance imaging (MRI) is growing at the fastest rate. According to “"US Markets for Imaged-Guided Surgery Products,"” published in November 2007 by Medtech Insight, MRI systems used in surgery or interventional procedures accounted for 12.5% of the $1.24 billion in surgical interventional imaging sales in the US in 2006, and procedure volumes are expected to grow at a compound annual rate of 9.2% through the year 2011. While it's obvious that the diagnostic imaging giants are positioned to enjoy the growth in emerging applications of MRI, start-ups can profit too.
- Drug Delivery
- Implantable Devices
Diagnostic Imaging Equipment & Supplies
- MRI, NMR
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Biophan Technologies Inc.